EP1480950A4 - Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix - Google Patents
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ixInfo
- Publication number
- EP1480950A4 EP1480950A4 EP03713610A EP03713610A EP1480950A4 EP 1480950 A4 EP1480950 A4 EP 1480950A4 EP 03713610 A EP03713610 A EP 03713610A EP 03713610 A EP03713610 A EP 03713610A EP 1480950 A4 EP1480950 A4 EP 1480950A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- calcium
- processes
- atorvastatin hemi
- novel
- forms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35718102P | 2002-02-15 | 2002-02-15 | |
US357181P | 2002-02-15 | ||
US42532502P | 2002-11-12 | 2002-11-12 | |
US425325P | 2002-11-12 | ||
PCT/US2003/005384 WO2003070702A1 (en) | 2002-02-15 | 2003-02-19 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1480950A1 EP1480950A1 (en) | 2004-12-01 |
EP1480950A4 true EP1480950A4 (en) | 2005-05-18 |
Family
ID=27760457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03713610A Withdrawn EP1480950A4 (en) | 2002-02-15 | 2003-02-19 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1480950A4 (en) |
JP (2) | JP2005519076A (en) |
KR (1) | KR100724515B1 (en) |
CN (1) | CN100406436C (en) |
AU (1) | AU2003217653A1 (en) |
CA (1) | CA2475864A1 (en) |
DE (1) | DE03713610T1 (en) |
ES (1) | ES2241507T1 (en) |
HR (1) | HRP20040768A2 (en) |
IS (1) | IS7402A (en) |
MX (1) | MXPA04007939A (en) |
NO (1) | NO20043842L (en) |
PL (1) | PL372303A1 (en) |
WO (1) | WO2003070702A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL163594A0 (en) | 2002-02-19 | 2005-12-18 | Teva Pharma | Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent |
AU2003297594A1 (en) * | 2002-11-28 | 2004-06-23 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
CA2573771C (en) | 2004-07-20 | 2011-05-10 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
DE202005020766U1 (en) * | 2004-07-22 | 2006-10-05 | Teva Pharmaceutical Industries Ltd. | New crystal forms of atorvastatin hemi-calcium |
WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
RU2409563C2 (en) * | 2005-04-08 | 2011-01-20 | Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг | Novel polymorphous form of crystalline hemicalcium salt of atorvastatin |
DE602006014193D1 (en) | 2005-11-21 | 2010-06-17 | Warner Lambert Co | NEW FORMS OF A R- (R *, R *) U-2- (4-FLUORPHENYL) -B, D-DIHYDROXY-5- (1-METHYLETHYL) -3-PHENYL-4-E (PHENYLAMINO) CARBONYLU-1H- pYRROLE-1-heptanoic MAGNESIUM |
KR20100023059A (en) | 2005-12-13 | 2010-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
EP2132171A4 (en) | 2007-03-02 | 2010-11-17 | Dong A Pharm Co Ltd | Novel crystal forms of pyrrolylheptanoic acid derivatives |
KR20120011249A (en) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same |
KR101324862B1 (en) * | 2011-07-12 | 2013-11-01 | (주)에이에스텍 | Spherical particle of clopidogrel bisulfate, pharmaceutical composition comprising the same and method of preparation thereof |
MX2021001169A (en) | 2013-11-15 | 2023-02-10 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof. |
CN105055357A (en) * | 2015-09-25 | 2015-11-18 | 青岛华之草医药科技有限公司 | Atorvastatin calcium composition tablet for treating hypercholesteremia |
KR101723783B1 (en) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003959A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
WO1997003958A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
WO2001036384A1 (en) * | 1999-11-17 | 2001-05-25 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
WO2001044181A1 (en) * | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
WO2001044180A1 (en) * | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
WO2002041834A2 (en) * | 2000-11-03 | 2002-05-30 | Teva Pharmaceutical Industries, Ltd. | Atorvastatin hemi-calcium form vii |
WO2002043732A1 (en) * | 2000-11-30 | 2002-06-06 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2002051804A1 (en) * | 2000-12-27 | 2002-07-04 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of atorvastatin |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
WO2003004470A1 (en) * | 2001-06-29 | 2003-01-16 | Warner-Lambert Company Llc | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
WO2003011826A1 (en) * | 2001-07-30 | 2003-02-13 | Dr. Reddy's Laboratories Ltd. | Crystalline forms vi and vii of atorvastatin calcium |
WO2003050085A1 (en) * | 2001-12-12 | 2003-06-19 | Ivax Corporation | CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1) |
WO2004022053A1 (en) * | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
-
2003
- 2003-02-19 DE DE03713610T patent/DE03713610T1/en active Pending
- 2003-02-19 CN CNB038082071A patent/CN100406436C/en not_active Expired - Fee Related
- 2003-02-19 PL PL03372303A patent/PL372303A1/en not_active Application Discontinuation
- 2003-02-19 WO PCT/US2003/005384 patent/WO2003070702A1/en active Application Filing
- 2003-02-19 MX MXPA04007939A patent/MXPA04007939A/en unknown
- 2003-02-19 CA CA002475864A patent/CA2475864A1/en not_active Abandoned
- 2003-02-19 AU AU2003217653A patent/AU2003217653A1/en not_active Abandoned
- 2003-02-19 JP JP2003569609A patent/JP2005519076A/en not_active Withdrawn
- 2003-02-19 EP EP03713610A patent/EP1480950A4/en not_active Withdrawn
- 2003-02-19 KR KR1020047012591A patent/KR100724515B1/en not_active IP Right Cessation
- 2003-02-19 ES ES03713610T patent/ES2241507T1/en active Pending
-
2004
- 2004-08-13 IS IS7402A patent/IS7402A/en unknown
- 2004-08-25 HR HR20040768A patent/HRP20040768A2/en not_active Application Discontinuation
- 2004-09-14 NO NO20043842A patent/NO20043842L/en not_active Application Discontinuation
-
2009
- 2009-06-08 JP JP2009137400A patent/JP2009235083A/en active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003959A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
WO1997003958A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
WO2001036384A1 (en) * | 1999-11-17 | 2001-05-25 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
WO2001044181A1 (en) * | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
WO2001044180A1 (en) * | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
WO2002041834A2 (en) * | 2000-11-03 | 2002-05-30 | Teva Pharmaceutical Industries, Ltd. | Atorvastatin hemi-calcium form vii |
WO2002043732A1 (en) * | 2000-11-30 | 2002-06-06 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2002051804A1 (en) * | 2000-12-27 | 2002-07-04 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of atorvastatin |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
WO2003004470A1 (en) * | 2001-06-29 | 2003-01-16 | Warner-Lambert Company Llc | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
WO2003011826A1 (en) * | 2001-07-30 | 2003-02-13 | Dr. Reddy's Laboratories Ltd. | Crystalline forms vi and vii of atorvastatin calcium |
WO2003050085A1 (en) * | 2001-12-12 | 2003-06-19 | Ivax Corporation | CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1) |
WO2004022053A1 (en) * | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
Non-Patent Citations (1)
Title |
---|
See also references of WO03070702A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2475864A1 (en) | 2003-08-28 |
CN1646490A (en) | 2005-07-27 |
JP2005519076A (en) | 2005-06-30 |
HRP20040768A2 (en) | 2005-06-30 |
DE03713610T1 (en) | 2005-10-20 |
AU2003217653A1 (en) | 2003-09-09 |
JP2009235083A (en) | 2009-10-15 |
NO20043842L (en) | 2004-09-14 |
PL372303A1 (en) | 2005-07-11 |
ES2241507T1 (en) | 2005-11-01 |
EP1480950A1 (en) | 2004-12-01 |
IS7402A (en) | 2004-08-13 |
MXPA04007939A (en) | 2004-11-26 |
CN100406436C (en) | 2008-07-30 |
KR20040081202A (en) | 2004-09-20 |
KR100724515B1 (en) | 2007-06-04 |
WO2003070702A1 (en) | 2003-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1480950A4 (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix | |
HUP0600538A2 (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
PL377555A1 (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
HRP20150163T1 (en) | Process for the preparation of n-substituted 2-cyanopyrrolidines | |
HK1084114A1 (en) | Compounds for synthesizing intermediate useful in the preparation of atorvastatin | |
WO2003070725A3 (en) | Process for preparing indolinone derivatives | |
AU2003230457A1 (en) | Compression of containers | |
IL180708A0 (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation | |
IL173012A0 (en) | Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin | |
AU2003297594A1 (en) | Crystalline form f of atorvastatin hemi-calcium salt | |
HK1081950A1 (en) | 1-Oxa-dibenzoazolenes as inhibitors of thmour necrosis factor production and intermediates for the preparation thereof | |
EP1547993A4 (en) | Process for preparation of spirofluorenols | |
AU2002367890A1 (en) | Process for the preparation of 4-methyl-thiazole-5-carbaldehyde intermediate | |
AU2003216848A1 (en) | Deracemisation of amines | |
AU2003217438A1 (en) | Novel crystalline forms of levetiracetam | |
PL1685104T3 (en) | Processes for the preparation of n-substituted phthalimides | |
AU2003302645A1 (en) | Synthesis of pyrrolidine compound and salt thereof | |
AU2003272080A1 (en) | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate | |
AU2003262704A1 (en) | Synthesis of gatifloxacin | |
AU2003235129A1 (en) | Process for preparation of 2-aminoketones | |
AU2003200836A1 (en) | Method for the preparation of matairesinol | |
AU2003296482A1 (en) | Tetracyclines as anti-fungal agents for treatment of ringworm | |
LT2004018A (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
AU2002249557A1 (en) | COMBUSTION PROCESS FOR THE PREPARATION OF LiCoVO4 | |
AU2003209670A1 (en) | Novel crystalline forms of trandolapril |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040809 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050406 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 3/06 B Ipc: 7A 61K 31/40 B Ipc: 7C 07D 207/34 A |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: PP Ref document number: 20050300013 Country of ref document: GR |
|
EL | Fr: translation of claims filed | ||
DET | De: translation of patent claims | ||
17Q | First examination report despatched |
Effective date: 20081105 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090516 |